TEL AVIV, Israel, June 18, 2019 /PRNewswire/ - Therapix Biosciences Ltd. ("Therapix" or "the Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based...
Therapix Biosciences Ltd.
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
Biotechnology
1d
5d
1m
6m
1y
Max
Therapix Biosciences Ltd. News
18 Jun
Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive
TEL AVIV, Israel , May 29, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development...
Gainers: Avianca Holdings (NYSE: AVH ) +29% . Outlook Therapeutics (NASDAQ: OTLK ) +28% . Hibbett Sports (NASDAQ: HIBB ) +21% . Total System Services (NYSE: TSS ) +16% . Cavco Industries (NASDAQ: CVCO...
24 May
The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point...
23 May
Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Co
TEL AVIV, Israel , May 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development...
28 Mar
Therapix Biosciences Announces Pricing of $2.25 Million Registered Direct Offering
TEL AVIV, Israel, March 28, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based...
Therapix Biosciences (NASDAQ: TRPX ) has entered into definitive agreements with several institutional investorsproviding for the issuance of an aggregate of 642,853 ADS at a price of $3.50/ADS in a...
TEL AVIV, Israel, March 19, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based...
Cannabis News On Dec. 20, President Trump signed the Agriculture Improvement Act of 2018 into law, legalizing hemp in the U.S. Among other things, this new law changes certain federal authorities relating...
TEL AVIV, Israel , Dec. 21, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing ...
About Therapix Biosciences Ltd.
With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
We have four clinical programs to treat underserved central nervous system disorders
THX-110: A drug candidate platform for the treatment of symptoms related to Tourette syndrome (TS), as well as Obstructive Sleep Apnea (OSA) and chronic pain.
The THX-110 program takes a unique approach to cannabinoid formulation using the “Entourage Effect” hypothesis (i.e. in which Endocannabinoid system constituents work synergistically together). THX-110 is a proprietary combination drug based on dronabinol and PEA. PEA is a cannabinoid mimetic lipid molecule, which naturally occurs in various plant and animal sources.
THX-130: An “Ultra Low-Dose” THC targeting the high value and unserved market of Mild Cognitive Impairment (MCI), using a unique and proprietary drug development and delivery dosage platform.
THX-150: A drug candidate intended for the treatment of infectious diseases. It consists of a selected antibacterial agent, with THC or a combination of THC and PEA, to potentially exert antimicrobial synergy.
THX-160: An innovative and proprietary CB2 receptor agonist formulation intended for the treatment of pain. This specific CB2 receptor agonist was synthesized by Professor Raphael Mechoulam, Ph.D.
$ 0.10
-11.89%
Open:
0.11
High:
0.12
Low:
0.09
Market cap:
9.011 M
Symbol:
TRPX
Contact info
Phone:
+972–3-6167055
+972–3-6167056
Address:
Ariel Sharon St 4, Giv'atayim, Israel
